Cargando…

Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer’s disease: a network meta-analysis of 41 randomized controlled trials

BACKGROUND: Cholinesterase inhibitors and memantine have been approved for management of Alzheimer’s disease (AD), but there has been no consensus about the choice of various types and doses of drugs at different stages. Hence, we compared and ranked the efficacy and tolerability of these available...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dou, Kai-Xin, Tan, Meng-Shan, Tan, Chen-Chen, Cao, Xi-Peng, Hou, Xiao-He, Guo, Qi-Hao, Tan, Lan, Mok, Vincent, Yu, Jin-Tai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309083/ https://www.ncbi.nlm.nih.gov/pubmed/30591071 http://dx.doi.org/10.1186/s13195-018-0457-9

Ejemplares similares

Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease
por: Parsons, Chris G., et al.
Publicado: (2013)

Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease
por: Rountree, Susan D, et al.
Publicado: (2009)

Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review
por: Farrimond, Lucy E, et al.
Publicado: (2012)

Memantine combined with an acetyl cholinesterase inhibitor – hope for the future?
por: Fox, Chris, et al.
Publicado: (2006)

Combination Therapy with Cholinesterase Inhibitors and Memantine for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
por: Matsunaga, Shinji, et al.
Publicado: (2015)

Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer's Disease and Other Dementias
por: Muayqil, Taim, et al.
Publicado: (2012)

Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis
por: Kennedy, Richard E., et al.
Publicado: (2018)

The Alzheimer's disease THErapy with NEuroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild-to-moderate Alzheimer's disease stable on cholinesterase inhibitors or memantine—A randomized, double-blind, placebo-controlled trial
por: Chen, Christopher L.H., et al.
Publicado: (2019)

Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta-analysis
por: Meng, Yan-Hong, et al.
Publicado: (2019)

A Real-world Analysis of Treatment Patterns for Cholinesterase Inhibitors and Memantine among Newly-diagnosed Alzheimer’s Disease Patients
por: Bent-Ennakhil, Nawal, et al.
Publicado: (2017)

Important Error in ‘Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer's Disease and Other Dementias’ by Muayqil and Camicioli
por: Tariot, Pierre N., et al.
Publicado: (2014)

Comparative Value of Cholinesterase Inhibitors and Memantine in Persons with Moderate-to-Severe Alzheimer’s Disease in the United States: A Cost-Effectiveness Analysis(1)
por: Yunusa, Ismaeel, et al.
Publicado: (2021)

Erratum to: Comparative Value of Cholinesterase Inhibitors and Memantine in Persons with Moderate-to-Severe Alzheimer’s Disease in the United States: A Cost-Effectiveness Analysis
Publicado: (2021)

Cholinesterase inhibitors as Alzheimer's therapeutics
por: Sharma, Kamlesh
Publicado: (2019)

Synthesis and bioevaluation of new tacrine-cinnamic acid hybrids as cholinesterase inhibitors against Alzheimer’s disease
por: Chen, Yao, et al.
Publicado: (2017)

Memantine: efficacy and safety in mild-to-severe Alzheimer’s disease
por: Tampi, Rajesh R, et al.
Publicado: (2007)

The Safety, Tolerability, and Efficacy of Once-Daily Memantine (28 mg): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Moderate-to-Severe Alzheimer’s Disease Taking Cholinesterase Inhibitors
por: Grossberg, George T., et al.
Publicado: (2013)

Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease
por: Hu, Ziheng, et al.
Publicado: (2018)

CHRNA7 Polymorphisms and Response to Cholinesterase Inhibitors in Alzheimer's Disease
por: Weng, Pei-Hsuan, et al.
Publicado: (2013)

Memantine ER Maintains Patient Response in Moderate to Severe Alzheimer’s Disease: Post Hoc Analyses From a Randomized, Controlled, Clinical Trial of Patients Treated With Cholinesterase Inhibitors
por: Grossberg, George T., et al.
Publicado: (2018)

Response to cholinesterase inhibitors affects lifespan in Alzheimer’s disease
por: Wattmo, Carina, et al.
Publicado: (2014)

Suboptimal Baseline Serum Vitamin B12 Is Associated With Cognitive Decline in People With Alzheimer’s Disease Undergoing Cholinesterase Inhibitor Treatment
por: Cho, Hsiao Shan, et al.
Publicado: (2018)

Potential Pharmacokinetic Drug–Drug Interaction Between Harmine, a Cholinesterase Inhibitor, and Memantine, a Non-Competitive N-Methyl-d-Aspartate Receptor Antagonist
por: Zhang, Yunpeng, et al.
Publicado: (2019)

Update on the use of memantine in Alzheimer’s disease
por: van Marum, Robert J
Publicado: (2009)

Concomitant Cholinesterase Inhibitor and Anticholinergic Drug Use Among Older Adults With Dementia
por: Carter, Elizabeth, et al.
Publicado: (2020)

Synthesis and Biological Evaluation of New Cholinesterase Inhibitors for Alzheimer’s Disease
por: Hussein, Weiam, et al.
Publicado: (2018)

Odor identification impairment and cholinesterase inhibitor treatment in Alzheimer's disease
por: Motter, Jeffrey N., et al.
Publicado: (2021)

TREML2 Mutation Mediate Alzheimer’s Disease Risk by Altering Neuronal Degeneration
por: Song, Ya-Nan, et al.
Publicado: (2019)

Comparison of cholinesterase inhibitor safety in real-world practice
por: Carney, Greg, et al.
Publicado: (2019)

Resveratrol as a Therapeutic Agent for Alzheimer's Disease
por: Ma, Teng, et al.
Publicado: (2014)

Memantine Derivatives as Multitarget Agents in Alzheimer’s Disease
por: Marotta, Giambattista, et al.
Publicado: (2020)

Exploring Mannosylpurines as Copper Chelators and Cholinesterase Inhibitors with Potential for Alzheimer’s Disease
por: Schino, Ignazio, et al.
Publicado: (2022)

Matrix Metalloproteinases and Their Multiple Roles in Alzheimer's Disease
por: Wang, Xiang-Xiang, et al.
Publicado: (2014)

Efficacy and Safety of Switching from Oral Cholinesterase Inhibitors to the Rivastigmine Transdermal Patch in Patients with Probable Alzheimer's Disease
por: Han, Hyun Jeong, et al.
Publicado: (2011)

Behavioral and Psychological Symptoms in Alzheimer's Disease
por: Li, Xiao-Ling, et al.
Publicado: (2014)

Effect of HMGCR genetic variation on neuroimaging biomarkers in healthy, mild cognitive impairment and Alzheimer's disease cohorts
por: Cao, Lei, et al.
Publicado: (2016)

Plant Terpenoids as the Promising Source of Cholinesterase Inhibitors for Anti-AD Therapy
por: Lai Shi Min, Shereen, et al.
Publicado: (2022)

Therapy of addition for Alzheimer's Disease: combination with galantamine and memantine
por: Zarra, Julio, et al.
Publicado: (2010)

Memantine-induced Myoclonus in a Patient with Alzheimer Disease
por: Murgai, Aditya A., et al.
Publicado: (2015)

Memantine prodrug as a new agent for Alzheimer’s Disease
por: Sestito, Simona, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nc63eetvnmcck4g2dfm1j1bjmk